Dr. Vuong Trieu, Developer of Novel Oncology and Immunotherapy Assets, Leads Oncotelic Therapeutics’ Commitment to Innovation, Life-Saving Therapies

Core Insights - Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative oncology and immunotherapy treatments, with a strong emphasis on addressing high unmet medical needs in cancer and rare pediatric indications [1][5] Company Overview - The company is led by Dr. Vuong Trieu, who has a significant impact on the biopharma industry through his extensive intellectual property portfolio, including over 500 filed patents and 75 issued patents [2][4] - Dr. Trieu's notable contributions include the co-invention of Abraxane, which was acquired by Celgene for $2.9 billion, and the development of Cynviloq, sold to NantPharma for $1.3 billion [2] Clinical Pipeline - Oncotelic's pipeline includes several key drug candidates: - OT-101 (TGF-β inhibitor): Currently in Phase 3 for pancreatic cancer, with potential applications in ARDS/COVID-19 [7] - OXi4503 (vascular disrupting agent): In Phase 2 for AML/MDS, moving towards pivotal Phase 3 design [7] - CA4P / Fosbretabulin: A late-stage oncology asset undergoing repositioning [7] - AL-101 (intranasal apomorphine): In Phase 2 for Parkinson's disease and sexual dysfunctions [7] - AL-102 (oligonucleotide antisense via intrathecal injection): In discovery stage for Alzheimer's disease [7] - Pediatric Rare Disease Programs: Targeting orphan indications with potential for Priority Review Vouchers (PRVs) [7] Intellectual Property and Strategic Position - The company's strategy is reinforced by Dr. Trieu's innovations, which form the cornerstone of Oncotelic's intellectual property portfolio, aimed at building value through differentiated biotechnology assets [4][5] - Oncotelic also engages in licensing and co-developing drug candidates through joint ventures, owning 45% of GMP Bio, which is advancing its own pipeline [6]